Source: https://www.law.cornell.edu/cfr/text/21/part-314
Timestamp: 2017-12-18 14:54:23
Document Index: 195172203

Matched Legal Cases: ['art 314', '§ 314', '§ 314', '§ 314', '§ 314', '§ 314', '§ 314', '§ 314', '§ 314', 'art 314']

CFR › Title 21 › Chapter I › Subchapter D › Part 314
Subpart A - General Provisions (§§ 314.1 - 314.3)
Subpart B - Applications (§§ 314.50 - 314.90)
Subpart C - Abbreviated Applications (§§ 314.92 - 314.99)
Subpart D - FDA Action on Applications and Abbreviated Applications (§§ 314.100 - 314.170)
Subpart E - Hearing Procedures for New Drugs (§§ 314.200 - 314.235)
Subpart G - Miscellaneous Provisions (§§ 314.410 - 314.445)
Subpart H - Accelerated Approval of New Drugs for Serious or Life-Threatening Illnesses (§§ 314.500 - 314.560)
Subpart I - Approval of New Drugs When Human Efficacy Studies Are Not Ethical or Feasible (§§ 314.600 - 314.650)
21 U.S.C. 321, 331, 351, 352, 353, 355, 355a, 355f, 356, 356a, 356b, 356c, 356e, 360cc, 371, 374, 379e, 379k-1.
Nomenclature changes to part 314 appear at 69 FR 13717, Mar. 24, 2004; 81 FR 69639, Oct. 6, 2016.
Title 21 published on 20-Nov-2017 04:18